Researcher Profiles

Return to member profile

Joseph R. Bertino, MD

Publications since 2011

Tedeschi, P. M. Kathari, Y. K. Farooqi, I. N. Bertino, J. R. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts. Cancer Chemother Pharmacol, In process, . (PMID: 25205429)

Munshi, P. N. Lubin, M. Bertino, J. R. 6-Thioguanine: A Drug With Unrealized Potential for Cancer Therapy. Oncologist, 19:760-765, . (PMID: 24928612, PMCID: PMC4077447)

Capaccione, K. M. Hong, X. Morgan, K. M. Liu, W. Bishop, J. M. Liu, L. Markert, E. Deen, M. Minerowicz, C. Bertino, J. R. Allen, T. Pine, S. R. Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma. Oncotarget, 5:3636-3650, . (PMID: 25004243, PMCID: PMC4116509)

Xie, X. Bansal, N. Shaik, T. Kerrigan, J. E. Minko, T. Garbuzenko, O. Abali, E. E. Johnson-Farley, N. Banerjee, D. Scotto, K. W. Bertino, J. R. A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts. Oncotarget, 5:901-907, . (PMID: 24658650, PMCID: PMC4011592)

Bansal, N. Davis, S. Tereshchenko, I. Budak-Alpdogan, T. Zhong, H. Stein, M. N. Kim, I. Y. Dipaola, R. S. Bertino, J. R. Sabaawy, H. E. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate, 74:187-200, . (PMID: 24154958, PMCID: PMC3939797)

Xie, X. Kerrigan, J. E. Minko, T. Garbuzenko, O. Lee, K. C. Scarborough, A. Abali, E. E. Budak-Alpdogan, T. Johnson-Farley, N. Banerjee, D. Scotto, K. W. Bertino, J. R. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer. Cancer Biol Ther, 14:742-751, . (PMID: 23792570)

Hsieh, Y. C. Tedeschi, P. Adebisi Lawal, R. Banerjee, D. Scotto, K. Kerrigan, J. E. Lee, K. C. Johnson-Farley, N. Bertino, J. R. Abali, E. E. Enhanced Degradation of Dihydrofolate Reductase through Inhibition of NAD Kinase by Nicotinamide Analogs. Mol Pharmacol, 83:339-353, . (PMID: 23197646, PMCID: PMC3558814)

Bertino, J. R. Vazquez, A. Tedeschi, P. M. Over expression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Res, 73:478-482, . (PMID: 23135910)

Tedeschi, P. M. Markert, E. K. Gounder, M. Lin, H. Dvorzhinski, D. Dolfi, S. C. Chan, L. L. Qiu, J. Dipaola, R. S. Hirshfield, K. M. Boros, L. G. Bertino, J. R. Oltvai, Z. N. Vazquez, A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis, 4:e877, . (PMID: 24157871, PMCID: PMC3920946)

Dolfi, S. C. Chan, L. L. Qiu, J. Tedeschi, P. M. Bertino, J. R. Hirshfield, K. M. Oltvai, Z. N. Vazquez, A. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab, 1:20, . (PMID: 24279929)

Budak-Alpdogan, T. Jeganathan, G. Lee, K. C. Mrowiec, Z. R. Medina, D. J. Todd, D. Moore, D. Bertino, J. R. Strair, R. Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice. Bone Marrow Transplant, 47:1569-1576, . (PMID: 22609880)

Roussel, B. Johnson-Farley, N. Kerrigan, J. E. Scotto, K. W. Banerjee, D. Felczak, K. Pankiewicz, K. W. Gounder, M. Lin, H. Abali, E. E. Bertino, J. R. A second target of benzamide riboside: Dihydrofolate reductase. Cancer Biol Ther, 13:1290-1298, . (PMID: 22954684, PMCID: PMC3493437)

Bertino, J. R. Lubin, M. Johnson-Farley, N. Chan, W. C. Goodell, L. Bhagavathi, S. Lack of Expression of MTAP in Uncommon T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk, 12:306-309, . (PMID: 23040436)

Lin, H. Gounder, M. K. Bertino, J. R. Kong, A. N. DiPaola, R. S. Stein, M. N. A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J Pharm Biomed Anal, 66:371-375, . (PMID: 22483642, PMCID: PMC3358459)

Gounder, M. K. Lin, H. Stein, M. Goodin, S. Bertino, J. R. Kong, A. N. DiPaola, R. S. A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. Biomed Chromatogr, 26:650-654, . (PMID: 21932382)

Collins, C. C. Volik, S. V. Lapuk, A. V. Wang, Y. Gout, P. W. Wu, C. Xue, H. Cheng, H. Haegert, A. Bell, R. H. Brahmbhatt, S. Anderson, S. Fazli, L. Hurtado-Coll, A. Rubin, M. A. Demichelis, F. Beltran, H. Hirst, M. Marra, M. Maher, C. A. Chinnaiyan, A. M. Gleave, M. Bertino, J. R. Lubin, M. Wang, Y. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther, 11:775-783, . (PMID: 22252602)

Barboza, N. M. Medina, D. J. Budak-Alpdogan, T. Aracil, M. Jimeno, J. M. Bertino, J. R. Banerjee, D. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol Ther, 13:114-122, . (PMID: 22336911, PMCID: PMC3336068)

Kamen, B. A. Bertino, J. R. Holcenberg, J. S. Bleyer, W. A. Are we getting closer to using methotrexate in an optimal manner? J Clin Oncol, 29:3493-4; author reply 3494, . (PMID: 21810689)

Bertino, J. R. Waud, W. R. Parker, W. B. Lubin, M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. Cancer Biol Ther, 11:627-632, . (PMID: 21301207, PMCID: PMC3084968)

Moroz, M. A. Kochetkov, T. Cai, S. Wu, J. Shamis, M. Nair, J. de Stanchina, E. Serganova, I. Schwartz, G. K. Banerjee, D. Bertino, J. R. Blasberg, R. G. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging. Clin Cancer Res, 17:1099-1110, . (PMID: 21245090, PMCID: PMC3079195)